Skip to Main Content

Advertisement intended for health care professionals

Umbrella Alt Text
Cart
header search
Search
Skip Nav Destination

Issue Archive

Volume 132, Issue 14
October 4 2018
Issue Cover

Table of Contents

BLOOD COMMENTARIES

Red Cells, Iron, and Erythropoiesis
A long sought after “receptor” for ERFE?
An-Sheng Zhang,Caroline A. Enns
View Articletitled, A long sought after “receptor” for ERFE?
Lymphoid Neoplasia
M-protein–related disorders: MGCS
Joan Bladé,M. Teresa Cibeira
View Articletitled, M-protein–related disorders: MGCS
CLINICAL TRIALS AND OBSERVATIONS
Next-generation therapy for follicular lymphoma
Clinical Trials & Observations
Loretta J. Nastoupil
View Articletitled, Next-generation therapy for follicular lymphoma
IMMUNOBIOLOGY AND IMMUNOTHERAPY
Getting the most from your CAR target
David M. Barrett
View Articletitled, Getting the most from your CAR target
MYELOID NEOPLASIA
MBD4: guardian of the epigenetic galaxy
Lambert Busque,Lucy A. Godley
View Articletitled, <em>MBD4</em>: guardian of the epigenetic galaxy
MYELOID NEOPLASIA
Mice no longer immune to immunomodulatory drugs
Flavia Pichiorri
View Articletitled, Mice no longer immune to immunomodulatory drugs

PLENARY PAPER

Red Cells, Iron, and Erythropoiesis
Erythroferrone inhibits the induction of hepcidin by BMP6
Brief Report
João Arezes,Niall Foy,Kirsty McHugh,Anagha Sawant,Doris Quinkert,Virginie Terraube,Alette Brinth,May Tam,Edward R. LaVallie,Stephen Taylor,Andrew E. Armitage,Sant-Rayn Pasricha,Orla Cunningham,Matthew Lambert,Simon J. Draper,Reema Jasuja,Hal Drakesmith
View Articletitled, Erythroferrone inhibits the induction of hepcidin by BMP6
Supplemental data

SPECIAL REPORT

Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications
Jean-Paul Fermand,Frank Bridoux,Angela Dispenzieri,Arnaud Jaccard,Robert A. Kyle,Nelson Leung,Giampaolo Merlini
View Articletitled, Monoclonal gammopathy of clinical significance: a novel concept with therapeutic implications

CLINICAL TRIALS AND OBSERVATIONS

An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma
Clinical Trials & Observations
Franck Morschhauser,Gilles Salles,Steven Le Gouill,Herve Tilly,Catherine Thieblemont,Krimo Bouabdallah,Bettina Fabiani,Cédric Ménard,Karin Tarte,Guillaume Cartron,Roch Houot
View Articletitled, An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma

IMMUNOBIOLOGY AND IMMUNOTHERAPY

Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Irene Scarfò,Maria Ormhøj,Matthew J. Frigault,Ana P. Castano,Selena Lorrey,Amanda A. Bouffard,Alexandria van Scoyk,Scott J. Rodig,Alexandra J. Shay,Jon C. Aster,Frederic I. Preffer,David M. Weinstock,Marcela V. Maus
View Articletitled, Anti-CD37 chimeric antigen receptor T cells are active against B- and T-cell lymphomas
Supplemental data

LYMPHOID NEOPLASIA

North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
Urvi A. Shah,Elaine Y. Chung,Orsi Giricz,Kith Pradhan,Keisuke Kataoka,Shanisha Gordon-Mitchell,Tushar D. Bhagat,Yun Mai,Yongqiang Wei,Elise Ishida,Gaurav S. Choudhary,Ancy Joseph,Ronald Rice,Nadege Gitego,Crystall Parrish,Matthias Bartenstein,Swati Goel,Ioannis Mantzaris,Aditi Shastri,Olga Derman,Adam Binder,Kira Gritsman,Noah Kornblum,Ira Braunschweig,Chirag Bhagat,Jeff Hall,Armin Graber,Lee Ratner,Yanhua Wang,Seishi Ogawa,Amit Verma,B. Hilda Ye,Murali Janakiram
View Articletitled, North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies
Supplemental data
Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group
Clinical Trials & Observations
Dennis A. Eichenauer,Annette Plütschow,Lena Schröder,Michael Fuchs,Boris Böll,Bastian von Tresckow,Volker Diehl,Peter Borchmann,Andreas Engert
View Articletitled, Relapsed and refractory nodular lymphocyte-predominant Hodgkin lymphoma: an analysis from the German Hodgkin Study Group

MYELOID NEOPLASIA

MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
Mathijs A. Sanders,Edward Chew,Christoffer Flensburg,Annelieke Zeilemaker,Sarah E. Miller,Adil S. al Hinai,Ashish Bajel,Bram Luiken,Melissa Rijken,Tamara Mclennan,Remco M. Hoogenboezem,François G. Kavelaars,Stefan Fröhling,Marnie E. Blewitt,Eric M. Bindels,Warren S. Alexander,Bob Löwenberg,Andrew W. Roberts,Peter J. M. Valk,Ian J. Majewski
View Articletitled, MBD4 guards against methylation damage and germ line deficiency predisposes to clonal hematopoiesis and early-onset AML
Supplemental data
CrbnI391V is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Emma C. Fink,Marie McConkey,Dylan N. Adams,Saurav D. Haldar,James A. Kennedy,Andrew A. Guirguis,Namrata D. Udeshi,D. R. Mani,Michelle Chen,Brian Liddicoat,Tanya Svinkina,Andrew T. Nguyen,Steven A. Carr,Benjamin L. Ebert
View Articletitled, <em>Crbn</em><sup>I391V</sup> is sufficient to confer in vivo sensitivity to thalidomide and its derivatives in mice
Supplemental data

BLOOD WORK

An unexpected association of hematologic malignancies
Nicolas Athanase,Elise Frébet
View Articletitled, An unexpected association of hematologic malignancies
All Issues

Advertisement intended for health care professionals

Preclinical efficacy of potent and selective menin-KMT2A inhibitor JNJ-75276617 in KMT2A- and NPM1-altered leukemias
Genotype-Phenotype Correlations in Chronic Granulomatous Disease: Insights From a Large National Cohort
GVHD targets organoid-forming bile duct stem cells via a TGF-β-dependent manner
Quadriparesis and paraparesis following chimeric antigen receptor T-cell (CART) therapy in children and adolescents
How I Treat on Infant Acute Lymphoblastic Leukemia

Advertisement intended for health care professionals

Advertisement intended for health care professionals

  • American Society of Hematology
  • 2021 L Street NW, Suite 900
  • Washington, DC 20036
  • TEL +1 202-776-0544
  • FAX +1 202-776-0545

ASH Publications

American Society of Hematology

Copyright 2024 by American Society of Hematology
 
Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals